Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 215 results for arthritis

  1. Assessment of disease severity and impact:- In children, young people and adults with psoriasis, can tools be developed and/or existing ones further refined and validated to: - assess disease severity and impact in both non-specialist and specialist healthcare settings, to facilitate assessment, appropriate referral, treatment planning and measurement of outcomes - measure burden and cumulative effect of disease activity, severity and impact for people with both psoriasis and psoriatic arthritis?

    activity, severity and impact for people with both psoriasis and psoriatic arthritis? Any explanatory notes(if applicable) Why this is...

    Research recommendation
    Published
    9 June 2015

  2. Mosaicplasty for symptomatic articular cartilage defects of the knee (HTG463)

    Evidence-based recommendations on mosaicplasty in people with symptomatic articular cartilage defects of the knee. This involves taking healthy cartilage from the edge of the joint and inserting it into drilled tunnels in the damaged site.

    HealthTech guidance
    Published
    14 March 2018
    View recommendations

    Sections for HTG463

  3. Metatarsophalangeal joint replacement of the hallux (HTG87)

    Evidence-based recommendations on metatarsophalangeal joint replacement of the hallux. This involves removing the problem joint and replacing it with an artificial one.

    HealthTech guidance
    Published
    23 November 2005
    View recommendations

    Sections for HTG87

  4. Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis (HTG148)

    Evidence-based recommendations on arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis. This involves flushing the joint with fluid, which is introduced through small incisions in the knee.

    HealthTech guidance
    Published
    22 August 2007
    View recommendations

    Sections for HTG148

  5. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193)

    This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.

    NICE guideline
    Published
    7 April 2021
    View recommendations

    Sections for NG193

  6. Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) (HTG627)

    Evidence-based recommendations on synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus). This involves replacing damaged cartilage with an artificial (synthetic) implant.

    HealthTech guidance
    Published
    1 June 2022
    View recommendations

    Sections for HTG627

  7. Single-step scaffold insertion for repairing symptomatic chondral knee defects (HTG728)

    Evidence-based recommendations on single-step scaffold insertion for repairing symptomatic chondral knee defects. This involves inserting a scaffold into the damaged area of the knee to support regrowth and repair of the cartilage.

    HealthTech guidance
    Last updated
    5 August 2025
    View recommendations

    Sections for HTG728

  8. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued Reference number: GID-TAG402

    Technology appraisal guidance
    Discontinued

  9. Appeal panel membership

    The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.

  10. Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

    In development Reference number: GID-TA10598 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Juvenile idiopathic arthritis - adalimumab [ID385]

    Discontinued Reference number: GID-TAG400

    Technology appraisal guidance
    Discontinued

  12. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued Reference number: GID-TAG393

    Technology appraisal guidance
    Discontinued

  13. Canakinumab and tocilizumab for treating systemic juvenile idiopathic arthritis [ID983]

    Discontinued Reference number: GID-TA11241

    Technology appraisal guidance
    Discontinued

  14. Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

    Discontinued Reference number: GID-TA10180

    Technology appraisal guidance
    Discontinued

  15. Rapid escalation to systemic treatments:- In people with psoriasis, does early intervention with systemic treatments improve the long-term prognosis of psoriasis severity, comorbidities (including psoriatic arthritis), or treatment -related adverse effects, and are there any clinical (for example demographic or phenotypic) or laboratory (for example genetic or immune) biomarkers that can be used to identify those most likely to benefit from this treatment approach?

    long-term prognosis of psoriasis severity, comorbidities (including psoriatic arthritis), or treatment -related adverse effects, and are...

    Research recommendation
    Published
    9 June 2015